EAU 2023 | 2nd PIONEER Studyathon: which patients benefit most from the different treatment options for mHSPC?

Juan Gómez Rivas, MD, PhD, Clínico San Carlos University Hospital, Madrid, Spain, shares the results of the second PIONEER Studyathon designed to develop a prediction model to identify optimal treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC) using real-world data. The study demonstrated that real-world data is different to randomized clinical trial data, including mean age of patients with mHSPC and treatment patterns. The prediction model developed using the real-world data has an accuracy of 75% in predicting death within the first year of diagnosis. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.